Iterum Therapeutics Stock (NASDAQ:ITRM)
Previous Close
$1.12
52W Range
$0.62 - $2.50
50D Avg
$1.23
200D Avg
$1.51
Market Cap
$24.52M
Avg Vol (3M)
$267.14K
Beta
2.26
Div Yield
-
ITRM Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
ITRM Performance
Peer Comparison
Ticker | Company |
---|---|
HOTH | Hoth Therapeutics, Inc. |
CFRX | ContraFect Corporation |
ADIL | Adial Pharmaceuticals, Inc. |
AEZS | Aeterna Zentaris Inc. |
OCUP | Ocuphire Pharma, Inc. |
REVB | Revelation Biosciences, Inc. |
FBIO | Fortress Biotech, Inc. |
CTXR | Citius Pharmaceuticals, Inc. |
TNXP | Tonix Pharmaceuticals Holding Corp. |
DFFN | CervoMed Inc. |
FWBI | Entero Therapeutics, Inc. |
DRMA | Dermata Therapeutics, Inc. |
JAGX | Jaguar Health, Inc. |
EYEN | Eyenovia, Inc. |
VINC | Vincerx Pharma, Inc. |
ONTX | Traws Pharma, Inc. |
ACST | Acasti Pharma Inc. |
VRCA | Verrica Pharmaceuticals Inc. |
GRTX | Galera Therapeutics, Inc. |